| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $19,988,986 | 3 | 7 |
Sells | $25,546,110 | 39 | 93 |
| AKKARAJU SRINIVAS | director | 3 | $19.99M | 0 | $0 | $19.99M |
| Gilman Michael | director | 0 | $0 | 1 | $100,304 | $-100,304 |
| Reed Joshua | director | 0 | $0 | 1 | $160,463 | $-160,463 |
| Burow Kristina | director | 0 | $0 | 1 | $160,511 | $-160,511 |
| Brudnick Richard | director | 0 | $0 | 1 | $180,531 | $-180,531 |
| Peng Katie | director | 0 | $0 | 4 | $208,593 | $-208,593 |
| Sacco Tracey | Chief Commercial Officer | 0 | $0 | 2 | $379,145 | $-379,145 |
| Moore Erin | Interim PFO and PAO | 0 | $0 | 1 | $449,237 | $-449,237 |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $451,299 | $-451,299 |
| Woods Keith | Chief Operating Officer | 0 | $0 | 1 | $715,054 | $-715,054 |
| Sinha Vikas | Chief Financial Officer | 0 | $0 | 1 | $715,439 | $-715,439 |
| Parlavecchio Caryn | CHRO | 0 | $0 | 4 | $979,776 | $-979,776 |
| Ho Junlin | GENERAL COUNSEL | 0 | $0 | 3 | $1.04M | $-1.04M |
| Vaishnaw Akshay | President of R&D | 0 | $0 | 2 | $1.07M | $-1.07M |
| FLIER JEFFREY S. | director | 0 | $0 | 3 | $1.65M | $-1.65M |
| Hallal David | Chief Executive Officer | 0 | $0 | 1 | $2.45M | $-2.45M |
| Myles Edward H | COO & CFO | 0 | $0 | 1 | $5.07M | $-5.07M |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 10 | $9.76M | $-9.76M |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $19.99M and sold $25.55M worth of Scholar Rock Holding Corporation stock.
On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $22.51M and sold $33.3M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $19.99M.
The last purchase of 29,599 shares for transaction amount of $1.18M was made by AKKARAJU SRINIVAS (director) on 2025‑10‑07.
| 2026-02-23 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 8,484 0.0083% | $47.07 | $399,351 | -4.70% | |
| 2026-02-17 | Sale | Ho Junlin | GENERAL COUNSEL | 9,580 0.0094% | $46.53 | $445,740 | -0.17% | |
| 2026-02-17 | Sale | Parlavecchio Caryn | CHRO | 9,035 0.0089% | $46.53 | $420,382 | -0.17% | |
| 2026-02-17 | Sale | Marantz Jing L. | CHIEF MEDICAL OFFICER | 4,157 0.0041% | $46.53 | $193,418 | -0.17% | |
| 2026-02-17 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 7,989 0.0078% | $46.53 | $371,714 | -0.17% | |
| 2026-01-22 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 14,898 0.0143% | $46.71 | $695,938 | -3.67% | |
| 2026-01-16 | Sale | Ho Junlin | GENERAL COUNSEL | 8,016 0.0078% | $44.48 | $356,533 | +2.35% | |
| 2026-01-16 | Sale | Parlavecchio Caryn | CHRO | 6,600 0.0064% | $44.48 | $293,553 | +2.35% | |
| 2026-01-16 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 8,406 0.0082% | $44.48 | $373,880 | +2.35% | |
| 2026-01-16 | Sale | Marantz Jing L. | CHIEF MEDICAL OFFICER | 5,798 0.0056% | $44.48 | $257,882 | +2.35% | |
| 2026-01-14 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 13,112 0.0127% | $45.20 | $592,611 | +0.98% | |
| 2026-01-13 | Sale | Hallal David | Chief Executive Officer | 57,450 0.055% | $42.70 | $2.45M | +5.16% | |
| 2026-01-13 | Sale | Vaishnaw Akshay | President of R&D | 20,438 0.0196% | $42.70 | $872,703 | +5.16% | |
| 2026-01-13 | Sale | Woods Keith | Chief Operating Officer | 16,746 0.016% | $42.70 | $715,054 | +5.16% | |
| 2026-01-13 | Sale | Sinha Vikas | Chief Financial Officer | 16,755 0.016% | $42.70 | $715,439 | +5.16% | |
| 2025-12-16 | Sale | Peng Katie | director | 1,006 0.001% | $44.09 | $44,352 | +1.97% | |
| 2025-12-04 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 136,462 0.1338% | $45.21 | $6.17M | -0.01% | |
| 2025-10-07 | AKKARAJU SRINIVAS | director | 29,599 0.0311% | $39.92 | $1.18M | +11.37% | ||
| 2025-10-06 | AKKARAJU SRINIVAS | director | 113,025 0.1142% | $38.65 | $4.37M | +10.46% | ||
| 2025-10-03 | AKKARAJU SRINIVAS | director | 387,414 0.4033% | $37.27 | $14.44M | +17.25% |
| Hallal David | Chief Executive Officer | 1541645 1.5113% | $69.03M | 0 | 1 | |
| Vaishnaw Akshay | President of R&D | 595767 0.584% | $26.68M | 0 | 2 | |
| Sinha Vikas | Chief Financial Officer | 583245 0.5718% | $26.12M | 0 | 1 | |
| Woods Keith | Chief Operating Officer | 583254 0.5718% | $26.12M | 0 | 1 | |
| AKKARAJU SRINIVAS | director | 530038 0.5196% | $23.74M | 4 | 1 | |
| Ho Junlin | GENERAL COUNSEL | 241545 0.2368% | $10.82M | 0 | 8 | |
| Parlavecchio Caryn | CHRO | 169087 0.1658% | $7.57M | 0 | 11 | |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 126012 0.1235% | $5.64M | 0 | 7 | |
| Myles Edward H | COO & CFO | 111345 0.1092% | $4.99M | 0 | 14 | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 98445 0.0965% | $4.41M | 0 | 19 | |
| Moore Erin | Interim PFO and PAO | 82609 0.081% | $3.7M | 0 | 1 | |
| Sacco Tracey | Chief Commercial Officer | 71750 0.0703% | $3.21M | 0 | 4 | |
| Gilman Michael | director | 55216 0.0541% | $2.47M | 0 | 4 | |
| Peng Katie | director | 32908 0.0323% | $1.47M | 0 | 4 | |
| Burow Kristina | director | 21071 0.0207% | $943,559.38 | 0 | 1 | |
| Reed Joshua | director | 15732 0.0154% | $704,478.96 | 0 | 1 | |
| Brudnick Richard | director | 15057 0.0148% | $674,252.46 | 0 | 1 | |
| FLIER JEFFREY S. | director | 0 0% | $0 | 0 | 6 | |
| Invus Public Equities, L.P. | 10 percent owner | 9250005 9.068% | $414.22M | 4 | 3 | +12.47% |
| Invus Public Equities Advisors, LLC | director | 8850005 8.6759% | $396.3M | 2 | 0 | +3.94% |
| Samsara BioCapital GP, LLC | 10 percent owner | 6788609 6.655% | $303.99M | 1 | 0 | |
| SPRINGER TIMOTHY A | 3273519 3.2091% | $146.59M | 1 | 0 | +17.37% | |
| Nashat Amir | 2676311 2.6237% | $119.85M | 1 | 0 | +17.37% | |
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 2676311 2.6237% | $119.85M | 1 | 0 | +17.37% |
| Artal International S.C.A. | 10 percent owner | 450000 0.4411% | $20.15M | 1 | 0 | +17.37% |
| Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | 311991 0.3059% | $13.97M | 0 | 3 | |
| Carven Gregory John | Head of Research | 32734 0.0321% | $1.47M | 0 | 2 |
$66,736,176 | 136 | 27.54% | $4.23B | |
$193,151,375 | 134 | 8.18% | $4.51B | |
$52,263,649 | 70 | 1.18% | $3.77B | |
$224,466,286 | 46 | 28.97% | $4.56B | |
$477,065,869 | 34 | 82.05% | $5.23B | |
$1,275,975,557 | 32 | 19.44% | $3.84B | |
$61,717,660 | 28 | 36.84% | $4.08B | |
$5,066,938 | 27 | 26.38% | $4.68B | |
$27,105,902 | 21 | -16.06% | $4.82B | |
$74,605,681 | 14 | 47.06% | $5.07B | |
$57,686,748 | 13 | 21.11% | $5.68B | |
$91,269,919 | 12 | 12.86% | $3.91B | |
$2,477,801 | 11 | 4.98% | $4.62B | |
$3,073,199 | 10 | 16.77% | $5.42B | |
Scholar Rock Holding Corporation (SRRK) | $25,064,843 | 9 | 12.75% | $4.57B |
$1,711,150 | 9 | 31.59% | $4.01B | |
$2,246,813 | 6 | 70.15% | $4.67B | |
$50,990,767 | 2 | 19.79% | $4.13B | |
$7,600,000 | 1 | -4.05% | $5.3B |
| Increased Positions | 178 | +73.55% | 23M | +19.38% |
| Decreased Positions | 104 | -42.98% | 16M | -13.48% |
| New Positions | 79 | New | 3M | New |
| Sold Out Positions | 36 | Sold Out | 7M | Sold Out |
| Total Postitions | 316 | +30.58% | 124M | +5.91% |
| Fmr Llc | $599,717.00 | 13.74% | 14.01M | +177,203 | +1.28% | 2025-09-30 |
| Siren, L.L.C. | $395,900.00 | 9.07% | 9.25M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $294,595.00 | 6.75% | 6.88M | -2M | -21.44% | 2025-09-30 |
| Blackrock, Inc. | $289,336.00 | 6.63% | 6.76M | +64,307 | +0.96% | 2025-09-30 |
| Samsara Biocapital, Llc | $240,232.00 | 5.5% | 5.61M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $210,359.00 | 4.82% | 4.91M | +53,333 | +1.1% | 2025-09-30 |
| Wellington Management Group Llp | $194,564.00 | 4.46% | 4.55M | +3M | +124.5% | 2025-09-30 |
| Redmile Group, Llc | $167,111.00 | 3.83% | 3.9M | -24,583 | -0.63% | 2025-09-30 |
| State Street Corp | $161,061.00 | 3.69% | 3.76M | +688,807 | +22.41% | 2025-09-30 |
| Bellevue Group Ag | $138,866.00 | 3.18% | 3.24M | +297,242 | +10.09% | 2025-09-30 |